NO20030790D0 - Peptidseleksjonsmetode - Google Patents

Peptidseleksjonsmetode

Info

Publication number: NO20030790D0
Authority: NO; Norway
Prior art keywords: peptide; peptidseleksjonsmetode; mbp; peptides; molecule
Prior art date: 2000-08-21

Application number

NO20030790A

Other languages

English (en)

Other versions

NO20030790L (no

NO330535B1 (no

Inventor

David Cameron Wraith

Stephen Mark Anderton

Graziella Mazza

Mary Ponsford

Heather Barbara Streeter

Original Assignee

Apitope Technology Bristol Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-21

Filing date

2003-02-19

Publication date

2003-02-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20030790(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-08-21 Priority claimed from GB0020618A external-priority patent/GB0020618D0/en

2001-06-14 Priority claimed from GB0114547A external-priority patent/GB0114547D0/en

2003-02-19 Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd

2003-02-19 Publication of NO20030790D0 publication Critical patent/NO20030790D0/no

2003-04-22 Publication of NO20030790L publication Critical patent/NO20030790L/no

2011-05-09 Publication of NO330535B1 publication Critical patent/NO330535B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 abstract 3
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
102000043129 MHC class I family Human genes 0.000 abstract 1
108091054437 MHC class I family Proteins 0.000 abstract 1
230000030741 antigen processing and presentation Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
230000003614 tolerogenic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Rehabilitation Therapy (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)

NO20030790A 2000-08-21 2003-02-19 Fremgangsmate for a undersoke den tolerogene kapasitet til et peptid og fremgangsmate for selektering av et tolerogent peptid. NO330535B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0020618A GB0020618D0 (en)	2000-08-21	2000-08-21	Peptide selection method
GB0114547A GB0114547D0 (en)	2001-06-14	2001-06-14	Peptide selection method
PCT/GB2001/003702 WO2002016410A2 (en)	2000-08-21	2001-08-17	Peptide selection method

Publications (3)

Publication Number	Publication Date
NO20030790D0 true NO20030790D0 (no)	2003-02-19
NO20030790L NO20030790L (no)	2003-04-22
NO330535B1 NO330535B1 (no)	2011-05-09

Family

ID=26244875

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20030790A NO330535B1 (no)	2000-08-21	2003-02-19	Fremgangsmate for a undersoke den tolerogene kapasitet til et peptid og fremgangsmate for selektering av et tolerogent peptid.
NO20101441A NO337988B1 (no)	2000-08-21	2010-10-18	Tolerogent peptid, farmasøytisk preparat som omfatter det samme, samt dets anvendelse.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20101441A NO337988B1 (no)	2000-08-21	2010-10-18	Tolerogent peptid, farmasøytisk preparat som omfatter det samme, samt dets anvendelse.

Country Status (25)

Country	Link
US (4)	US20030191063A1 (no)
EP (3)	EP1731912B1 (no)
JP (1)	JP5431628B2 (no)
KR (1)	KR20030062321A (no)
CN (4)	CN1469883A (no)
AT (2)	ATE401343T1 (no)
AU (2)	AU7863701A (no)
BR (2)	BR0113400A (no)
CA (1)	CA2420949C (no)
CY (3)	CY1108558T1 (no)
CZ (1)	CZ307202B6 (no)
DE (2)	DE60134862D1 (no)
DK (3)	DK1918298T3 (no)
ES (3)	ES2310558T3 (no)
HK (1)	HK1052359B (no)
HU (3)	HU229489B1 (no)
IL (1)	IL154089A0 (no)
MX (1)	MXPA03001606A (no)
NO (2)	NO330535B1 (no)
NZ (1)	NZ523841A (no)
PH (1)	PH12013500208A1 (no)
PL (4)	PL213585B1 (no)
PT (3)	PT1311542E (no)
SI (3)	SI1731912T1 (no)
WO (1)	WO2002016410A2 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE401343T1 (de)	2000-08-21	2008-08-15	Apitope Technology Bristol Ltd	Tolerogenische peptide
GB0202399D0 (en)	2002-02-01	2002-03-20	Univ Bristol	Peptide
WO2007131210A2 (en) *	2006-05-05	2007-11-15	Opexa Therapeutics	T-cell vaccine
GB0710529D0 (en)	2007-06-01	2007-07-11	Circassia Ltd	Vaccine
CN103272227B (zh)	2007-08-15	2014-12-10	切尔卡西亚有限公司	针对过敏原去敏化的肽
WO2009056833A2 (en) *	2007-10-31	2009-05-07	Apitope Technology (Bristol) Limited	Composition
GB0723712D0 (en) *	2007-12-04	2008-01-16	Apitope Technology Bristol Ltd	Peptides
ITMI20080508A1 (it) *	2008-03-27	2009-09-28	Istituto Nazionale Di Genetica Molecolare	Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3
ITMI20080865A1 (it) *	2008-05-13	2009-11-14	Istituto Naz Di Genetica Molecolare Ingm	Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
US9085798B2 (en)	2009-04-30	2015-07-21	Prognosys Biosciences, Inc.	Nucleic acid constructs and methods of use
GB0908515D0 (en) *	2009-05-18	2009-06-24	Apitope Technology Bristol Ltd	Peptide
JP5709876B2 (ja)	2009-10-12	2015-04-30	ライフバイオラボラトリーズエルエルシーＬＩＦＥＢｉｏＬＡＢＯＲＡＴＯＲＩＥＳＬＬＣ	多発性硬化症治療用組成物
RU2448685C2 (ru) *	2009-11-30	2012-04-27	Российская Федерация в лице Министерства промышленности и торговли Российской Федерации	Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
SI2556171T1 (sl)	2010-04-05	2016-03-31	Prognosys Biosciences, Inc.	Prostorsko kodirane biološke analize
US20190300945A1 (en)	2010-04-05	2019-10-03	Prognosys Biosciences, Inc.	Spatially Encoded Biological Assays
US10787701B2 (en)	2010-04-05	2020-09-29	Prognosys Biosciences, Inc.	Spatially encoded biological assays
KR200457779Y1 (ko) *	2010-06-23	2012-01-06	이준혁	샤프펜슬
EP3150750B1 (en)	2011-04-08	2018-12-26	Prognosys Biosciences, Inc.	Peptide constructs and assay systems
GB201106254D0 (en)	2011-04-13	2011-05-25	Frisen Jonas	Method and product
PL397623A1 (pl) *	2011-12-30	2013-07-08	Napco S. Ar.L.	Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie
EP4592400A3 (en)	2012-10-17	2025-10-29	10x Genomics Sweden AB	Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
BR112015010625B1 (pt)	2012-11-12	2023-03-07	Apitope International Nv	Peptídeos
GB201300684D0 (en)	2013-01-15	2013-02-27	Apitope Int Nv	Peptide
EP2972366B1 (en)	2013-03-15	2020-06-17	Prognosys Biosciences, Inc.	Methods for detecting peptide/mhc/tcr binding
EP4219745B1 (en)	2013-06-25	2025-09-03	Prognosys Biosciences, Inc.	Spatially encoded biological assays using a microfluidic device
GB201314052D0 (en) *	2013-08-06	2013-09-18	Apitope Int Nv	Peptides
US10288608B2 (en)	2013-11-08	2019-05-14	Prognosys Biosciences, Inc.	Polynucleotide conjugates and methods for analyte detection
KR101503341B1 (ko)	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
WO2016103213A1 (en) *	2014-12-24	2016-06-30	Apitope International Nv	Composition
DK3901281T4 (da)	2015-04-10	2025-10-20	Illumina Inc	Rumligt adskilt, multipleks nukleinsyreanalyse af biologiske prøver
MX2018006789A (es)	2015-12-03	2019-02-13	Juno Therapeutics Inc	Receptores quimericos modificados y composiciones y metodos relacionados.
JP7174492B2 (ja) *	2017-01-04	2022-11-17	ウォルグファーマシューティカルズ（ハンジョウ）カンパニー，リミテッド	Ｓ－アレスチンペプチドおよびその治療的使用
GB201700095D0 (en) *	2017-01-04	2017-02-22	Apitope Int Nv	Composition
EP3565585B1 (en) *	2017-01-04	2024-11-13	Worg Pharmaceuticals (Zhejiang) Co., Ltd.	Therapeutic method using dose escalation protocol for tolerogenic peptides
US10174122B2 (en)	2017-01-06	2019-01-08	Eutilex Co., Ltd.	Anti-human 4-1BB antibodies and uses thereof
GB201909774D0 (en) *	2019-07-08	2019-08-21	Apitope Tech Bristol Limited	Method
RU2761617C2 (ru) *	2019-10-04	2021-12-13	Жаудат Гафурович Умеров	Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения
CN115038794A (zh)	2019-12-23	2022-09-09	10X基因组学有限公司	在基于分区的测定中使用固定生物样品的组合物和方法
GB201919222D0 (en)	2019-12-23	2020-02-05	Apitope Int Nv	Composition
TR201922305A2 (tr) *	2019-12-30	2021-07-26	T C Erciyes Ueniversitesi	Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi
US11732299B2 (en)	2020-01-21	2023-08-22	10X Genomics, Inc.	Spatial assays with perturbed cells
US11702693B2 (en)	2020-01-21	2023-07-18	10X Genomics, Inc.	Methods for printing cells and generating arrays of barcoded cells
US20210230681A1 (en)	2020-01-24	2021-07-29	10X Genomics, Inc.	Methods for spatial analysis using proximity ligation
US11835462B2 (en)	2020-02-11	2023-12-05	10X Genomics, Inc.	Methods and compositions for partitioning a biological sample
US11926863B1 (en)	2020-02-27	2024-03-12	10X Genomics, Inc.	Solid state single cell method for analyzing fixed biological cells
JP2023525079A (ja)	2020-05-06	2023-06-14	アンシス・エスア	フマレート関連疾患の併用療法
WO2021236929A1 (en)	2020-05-22	2021-11-25	10X Genomics, Inc.	Simultaneous spatio-temporal measurement of gene expression and cellular activity
US12265079B1 (en)	2020-06-02	2025-04-01	10X Genomics, Inc.	Systems and methods for detecting analytes from captured single biological particles

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1327162C (en)	1987-04-09	1994-02-22	Board Of Trustees Of The Leland Stanford Junior University (The)	Method for prophylactically treating an individual for an autoimmune disease
AU632991B2 (en)	1987-06-24	1993-01-21	Autoimmune, Inc.	Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) *	1988-06-23	1993-11-09	Anergen, Inc.	MHC conjugates useful in ameliorating autoimmunity
US6036957A (en) *	1990-03-30	2000-03-14	Autoimmune, Inc.	Suppression of T-cell proliferation using peptide fragments of myelin basic protein
IL165071A (en) *	1990-03-30	2008-06-05	Autoimmune Inc	A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
US5593698A (en) *	1990-10-31	1997-01-14	Autoimmune, Inc.	Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5817629A (en) *	1991-10-22	1998-10-06	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5989565A (en) *	1993-01-29	1999-11-23	University Of Pittsburgh	Elution and identification of T cell epitopes from viable cells
SI9520059A (en) *	1994-05-10	1997-08-31	Immulogic Pharma Corp	Compositions and treatment for multiple sclerosis.
AU7242994A (en)	1994-05-20	1995-12-18	United States Of America, As Represented By The Secretary Of The Army, The	Model for testing immunogenicity of peptides
US6329499B1 (en) *	1994-11-18	2001-12-11	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) *	1994-11-18	2001-06-26	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en) *	1994-11-18	2002-04-30	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU5851196A (en) *	1995-04-20	1996-11-07	Brigham And Women's Hospital	Modulation of cytokine patterns of human autoreactive t-cell clones
WO1997041440A1 (en) *	1996-04-26	1997-11-06	Rijksuniversiteit Te Leiden	Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes
EP0849275A1 (en) *	1996-09-26	1998-06-24	Rijksuniversiteit te Leiden	Mannosylated peptides
WO1999063945A2 (en)	1998-06-12	1999-12-16	Sloan-Kettering Institute For Cancer Research	Vaccination strategy to prevent and treat cancers
MY129566A (en) *	1999-01-19	2007-04-30	Nestle Sa	A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
ATE401343T1 (de)	2000-08-21	2008-08-15	Apitope Technology Bristol Ltd	Tolerogenische peptide
GB0202399D0 (en)	2002-02-01	2002-03-20	Univ Bristol	Peptide
US8314290B2 (en)	2004-12-21	2012-11-20	Monsanto Technology Llc	Temporal regulation of gene expression by MicroRNAs
WO2009056833A2 (en)	2007-10-31	2009-05-07	Apitope Technology (Bristol) Limited	Composition
GB0723712D0 (en)	2007-12-04	2008-01-16	Apitope Technology Bristol Ltd	Peptides

2001
- 2001-08-17 AT AT01956718T patent/ATE401343T1/de active
- 2001-08-17 PT PT01956718T patent/PT1311542E/pt unknown
- 2001-08-17 AT AT08002817T patent/ATE483729T1/de active
- 2001-08-17 CN CNA018176828A patent/CN1469883A/zh active Pending
- 2001-08-17 CN CN201210156712.3A patent/CN102764425B/zh not_active Expired - Fee Related
- 2001-08-17 ES ES01956718T patent/ES2310558T3/es not_active Expired - Lifetime
- 2001-08-17 SI SI200131032T patent/SI1731912T1/sl unknown
- 2001-08-17 MX MXPA03001606A patent/MXPA03001606A/es active IP Right Grant
- 2001-08-17 HU HU0300814A patent/HU229489B1/hu not_active IP Right Cessation
- 2001-08-17 EP EP06014901.0A patent/EP1731912B1/en not_active Expired - Lifetime
- 2001-08-17 DK DK08002817.8T patent/DK1918298T3/da active
- 2001-08-17 ES ES08002817T patent/ES2353347T3/es not_active Expired - Lifetime
- 2001-08-17 DK DK01956718T patent/DK1311542T3/da active
- 2001-08-17 HU HU1300358A patent/HU230233B1/hu not_active IP Right Cessation
- 2001-08-17 IL IL15408901A patent/IL154089A0/xx unknown
- 2001-08-17 AU AU7863701A patent/AU7863701A/xx active Pending
- 2001-08-17 PL PL395781A patent/PL213585B1/pl unknown
- 2001-08-17 EP EP01956718A patent/EP1311542B1/en not_active Expired - Lifetime
- 2001-08-17 DE DE60134862T patent/DE60134862D1/de not_active Expired - Lifetime
- 2001-08-17 SI SI200130860T patent/SI1311542T1/sl unknown
- 2001-08-17 DE DE60143234T patent/DE60143234D1/de not_active Expired - Lifetime
- 2001-08-17 ES ES06014901.0T patent/ES2439899T3/es not_active Expired - Lifetime
- 2001-08-17 BR BR0113400-0A patent/BR0113400A/pt not_active IP Right Cessation
- 2001-08-17 CN CN201210156674.1A patent/CN102784385B/zh not_active Expired - Fee Related
- 2001-08-17 US US10/362,264 patent/US20030191063A1/en not_active Abandoned
- 2001-08-17 JP JP2002521505A patent/JP5431628B2/ja not_active Expired - Fee Related
- 2001-08-17 SI SI200130983T patent/SI1918298T1/sl unknown
- 2001-08-17 PT PT08002817T patent/PT1918298E/pt unknown
- 2001-08-17 DK DK06014901.0T patent/DK1731912T3/da active
- 2001-08-17 PL PL399138A patent/PL215145B1/pl unknown
- 2001-08-17 BR BRPI0113400-0A patent/BRPI0113400B1/pt unknown
- 2001-08-17 HK HK03104592.1A patent/HK1052359B/en not_active IP Right Cessation
- 2001-08-17 NZ NZ523841A patent/NZ523841A/en not_active IP Right Cessation
- 2001-08-17 CZ CZ2003-512A patent/CZ307202B6/cs not_active IP Right Cessation
- 2001-08-17 PT PT60149010T patent/PT1731912E/pt unknown
- 2001-08-17 PL PL399137A patent/PL215187B1/pl unknown
- 2001-08-17 KR KR10-2003-7002514A patent/KR20030062321A/ko not_active Ceased
- 2001-08-17 HU HU1300357A patent/HU229377B1/hu not_active IP Right Cessation
- 2001-08-17 EP EP08002817A patent/EP1918298B1/en not_active Expired - Lifetime
- 2001-08-17 CA CA2420949A patent/CA2420949C/en not_active Expired - Lifetime
- 2001-08-17 CN CN2009101296721A patent/CN101633689B/zh not_active Expired - Fee Related
- 2001-08-17 PL PL364048A patent/PL217929B1/pl unknown
- 2001-08-17 WO PCT/GB2001/003702 patent/WO2002016410A2/en not_active Ceased
- 2001-08-17 AU AU2001278637A patent/AU2001278637B2/en not_active Ceased
2003
- 2003-02-19 NO NO20030790A patent/NO330535B1/no not_active IP Right Cessation
2007
- 2007-10-31 US US11/979,224 patent/US8343500B2/en not_active Expired - Fee Related
2008
- 2008-10-13 CY CY20081101132T patent/CY1108558T1/el unknown
2010
- 2010-10-18 NO NO20101441A patent/NO337988B1/no not_active IP Right Cessation
2011
- 2011-01-04 CY CY20111100017T patent/CY1111079T1/el unknown
2012
- 2012-12-06 US US13/706,540 patent/US8961986B2/en not_active Expired - Fee Related
2013
- 2013-01-31 PH PH12013500208A patent/PH12013500208A1/en unknown
- 2013-12-18 CY CY20131101143T patent/CY1114808T1/el unknown
2018
- 2018-03-20 US US15/926,637 patent/US20180311328A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2420949A1 (en)	2002-02-28
CN102764425B (zh)	2015-11-25
HUP0300814A2 (hu)	2003-10-28
SI1731912T1 (sl)	2014-05-30
IL154089A0 (en)	2003-07-31
EP1311542A2 (en)	2003-05-21
HU230233B1 (hu)	2015-10-28
NO20030790L (no)	2003-04-22
PH12013500208B1 (en)	2015-04-20
DK1731912T3 (da)	2014-01-06
EP1311542B1 (en)	2008-07-16
EP1731912B1 (en)	2013-09-25
US8961986B2 (en)	2015-02-24
MXPA03001606A (es)	2004-11-01
US20130156798A1 (en)	2013-06-20
EP1731912A2 (en)	2006-12-13
NO337988B1 (no)	2016-07-18
NZ523841A (en)	2004-07-30
DK1918298T3 (da)	2010-11-29
ES2353347T3 (es)	2011-03-01
CN102784385B (zh)	2015-11-25
CN102764425A (zh)	2012-11-07
SI1311542T1 (sl)	2009-02-28
CY1114808T1 (el)	2016-12-14
US20030191063A1 (en)	2003-10-09
US20080200368A1 (en)	2008-08-21
WO2002016410A2 (en)	2002-02-28
CN101633689A (zh)	2010-01-27
BR0113400A (pt)	2003-07-08
CY1111079T1 (el)	2015-06-11
KR20030062321A (ko)	2003-07-23
PL215145B1 (pl)	2013-10-31
EP1918298B1 (en)	2010-10-06
HK1178437A1 (en)	2013-09-13
PT1731912E (pt)	2013-12-17
EP1918298A3 (en)	2008-05-28
US20180311328A1 (en)	2018-11-01
PL399137A1 (pl)	2012-07-30
NO330535B1 (no)	2011-05-09
SI1918298T1 (sl)	2011-01-31
CZ307202B6 (cs)	2018-03-21
EP1918298A2 (en)	2008-05-07
PH12013500208A1 (en)	2015-04-20
AU2001278637B2 (en)	2006-05-25
ATE401343T1 (de)	2008-08-15
JP2004506921A (ja)	2004-03-04
PL215187B1 (pl)	2013-11-29
PL213585B1 (pl)	2013-03-29
NO20101441L (no)	2003-04-22
US8343500B2 (en)	2013-01-01
CN101633689B (zh)	2013-09-04
HU229377B1 (hu)	2013-11-28
EP1731912A3 (en)	2006-12-27
AU7863701A (en)	2002-03-04
DE60143234D1 (de)	2010-11-18
HK1052359B (en)	2008-11-14
HUP0300814A3 (en)	2005-11-28
PL217929B1 (pl)	2014-09-30
ATE483729T1 (de)	2010-10-15
CN102784385A (zh)	2012-11-21
CY1108558T1 (el)	2014-04-09
DE60134862D1 (de)	2008-08-28
WO2002016410A3 (en)	2002-09-12
PL399138A1 (pl)	2012-07-30
PT1311542E (pt)	2008-10-03
PT1918298E (pt)	2010-12-09
DK1311542T3 (da)	2008-11-10
ES2439899T3 (es)	2014-01-27
HU229489B1 (hu)	2014-01-28
HK1178793A1 (en)	2013-09-19
JP5431628B2 (ja)	2014-03-05
ES2310558T3 (es)	2009-01-16
BRPI0113400B1 (pt)	2018-05-15
HK1052359A1 (en)	2003-09-11
CA2420949C (en)	2012-01-03
CN1469883A (zh)	2004-01-21
PL364048A1 (en)	2004-12-13

Publication	Publication Date	Title
DE60134862D1 (de)	2008-08-28	Tolerogenische Peptide
CY1110862T1 (el)	2015-06-10	Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
AU2002229510A1 (en)	2002-08-19	Combined use of factor vii polypeptides and factor viii polypeptides
TR200001608T2 (tr)	2001-07-23	Amiloidojenik hastalığın önlenmesi ve tedavisi
AR245778A1 (es)	1994-02-28	Secuencia de nucleotido que codifica una proteina de membrana exterior de neisseria meningitis y uso de dicha proteina en preparaciones de vacuna
MY129566A (en)	2007-04-30	A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
NZ263344A (en)	1997-08-22	Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
DK0858504T3 (da)	2006-02-13	Diagnostiske midler mod og behandlinger af periodontale sygdomme
DK1429800T3 (da)	2009-04-27	Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
FI941860A0 (fi)	1994-04-21	Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys
DK0759772T3 (da)	2004-06-01	Tri-, tetra-, penta- og polypeptider og deres terapeutiske anvendelse som antidepressiva
EE200000478A (et)	2002-02-15	Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
PT999849E (pt)	2003-01-31	Utilizacao de lbp no tratamento da septicemia
WO2004080387A3 (en)	2009-03-26	Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins

Legal Events

Date	Code	Title	Description
2020-03-23	MM1K	Lapsed by not paying the annual fees